Abstract:Background:Cancer immunotherapy has emerged as a promising strategy against triple-negative breast cancer (TNBC). One of the immunosuppressive pathways involves programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1), but many patients derived little benefit from PD-1/PD-L1 checkpoint blockades treatment. Prior research has shown that MYC, a master transcription amplifier highly expressed in TNBC cells, can regulate the tumor immune microenvironment and constrain the efficacy of immunotherapy. This study aims to investigate the regulatory relationship between MYC and PD-L1, and whether a cyclin-dependent kinase (CDK) inhibitor that inhibits MYC expression in combination with anti-PD-L1 antibodies can enhance the response to immunotherapy.Methods:Public databases and TNBC tissue microarrays were used to study the correlation between MYC and PD-L1. The expression of MYC and PD-L1 in TNBCs was examined by quantitative real-time polymerase chain reaction and Western blotting. A patient-derived tumor xenograft (PDTX) model was used to evaluate the influence of a CDK7 inhibitor THZ1 on PD-L1 expression. Cell proliferation and migration were detected by 5-ethynyl-2 '-deoxyuridine (EdU) cell proliferation and cell migration assays. Tumor xenograft models were established for in vivo verification.Results:A high MYC expression level was associated with a poor prognosis and could alter the proportion of tumor-infiltrating immune cells (TIICs). The positive correlation between MYC and PD-L1 was confirmed by immunostaining samples from 165 TNBC patients. Suppression of MYC in TNBC caused a reduction in the levels of both PD-L1 messenger RNA and protein. In addition, antitumor immune response was enhanced in the TNBC cancer xenograft mouse model with suppression of MYC by CDK7 inhibitor THZ1.Conclusions:The combined therapy of CDK7 inhibitor THZ1 and anti-PD-L1 antibody appeared to have a synergistic effect, which might offer new insight for enhancing immunotherapy in TNBC.

The Antitumor Peptide M1-20 Induced the Degradation of CDK1 Through CUL4-DDB1-DCAF1-involved Ubiquitination.

Development of an Interfering Peptide M1-20 with Potent Anti-Cancer Effects by Targeting FOXM1.

The cell-penetrating FOXM1 N-terminus (M1-138) demonstrates potent inhibitory effects on cancer cells by targeting FOXM1 and FOXM1-interacting factor SMAD3

The Development of an Anti-Cancer Peptide M1-21 Targeting Transcription Factor FOXM1

Enhanced Anti-Tumor Response Upon Deficiency of Msn Kinase MINK1 in Mice

Reciprocal antagonism of PIN1-APC/C CDH1 governs mitotic protein stability and cell cycle entry

MUC1 peptide inhibits tumor cell proliferation by binding small MUC1 protein

CDK1 Switches Mitotic Arrest to Apoptosis by Phosphorylating Bcl‐2/Bax Family Proteins During Treatment with Microtubule Interfering Agents

The oncoprotein MUC1 facilitates breast cancer progression by promoting Pink1-dependent mitophagy via ATAD3A destabilization

Pharmacological Inhibition of BMK1 Suppresses Tumor Growth Through Promyelocytic Leukemia Protein.

Metadherin/Astrocyte Elevated Gene-1 Positively Regulates the Stability and Function of Forkhead Box M1 During Tumorigenesis

Discovery of Novel Antitumor Small-Molecule Agent with Dual Action of CDK2/p-RB and MDM2/p53

Mind Bomb 1 Promotes Pancreatic Cancer Proliferation by Activating Β-Catenin Signaling

Expression of human full-length MUC1 inhibits the proliferation and migration of a B16 mouse melanoma cell line.

Data from MUC1 Oncoprotein Blocks Glycogen Synthase Kinase 3β–Mediated Phosphorylation and Degradation of β-Catenin

The Cytoplasmic Domain of MUC1 Induces Hyperplasia in the Mammary Gland and Correlates with Nuclear Accumulation of Β-Catenin

E3 ligase MG53 suppresses tumor growth by degrading cyclin D1

MYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation

Inhibition of MYC Suppresses Programmed Cell Death Ligand-1 Expression and Enhances Immunotherapy in Triple-Negative Breast Cancer

Mucin1 mediates autocrine transforming growth factor beta signaling through activating the c-Jun N-terminal kinase/activator protein 1 pathway in human hepatocellular carcinoma cells.

Anti-tumor effect induced by recombinant mouse Muc1-MBP fusion protein in vivo